Sickle Cell Disease Market Snapshot: "The Time Has Come"

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Hand flip wooden cube with word change to chance, Personal development and career growth or change yourself concept - Image
Big changes are in store for the sickle cell disease treatment market • Source: Shutterstock

With one new drug on the market in the US and two more pending at the US Food and Drug Administration, 2020 is positioned to be a turning point for the treatment of sickle cell disease. Patients with the devastating blood disorder, which results in acute pain crises, long-term organ damage and a shortened lifespan, have had few treatment options, but the outlook for sickle cell R&D is brighter than it has been.

"The time has come. We are at the cusp of improving the quality of life for people with sickle cell...

More from Market Snapshot

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.